Intellectual Property & Technology Transfer

training & workshop

TUESDAY, 24 SEPTEMBER 2019, Sofia, Bulgaria

We specialise in providing scientifically-minded and commercially-focused IP advice for your business.

Microbiology, Virology, Oncology, Immunology, Diagnostics,
Gene-editing, RNAi, Gene-therapy, Vaccines.

Biochemistry, Bio-pharmaceuticals, Pharmaceutical formulations, Peptide-therapeutics and Molecular Biology.

Priority IP Ltd is an independent intellectual property practice based in England operating in alliance with US law firms Kenealy Vaidya LLP and Dunlap Bennet & Ludwig LLP.

Our joint blend of scientific, commercial and litigation skills are used in lasting partnerships with our global clients to build a market focused and robust IP position. We help our global clients not only to obtain patents but we also use our scientific expertise and in-house experience to identify where real value can be enhanced or extracted, whether through IP strategic advice, selective licensing, work-around, collaborations or enforcement.

Our Services

IP strategy and portfolio management

We can support you with a full range of strategic intellectual property management services.

Patents

Irrespective of the size or nature of your enterprise a strategic approach to protecting your ideas is essential.

IP Due Diligence

For us, understanding that the IP due diligence exercise is crucial to the decision-making process is essential to our client's success.

Oppositions and Appeals

Our patent attorney is experienced advocate before the EPO Opposition Divisions and Boards of Appeal.

Find out more

Latest News

Can you protect herbal & food supplements with patents?

The answer is ‘certainly yes‘ – provided, however, the product or formulation is new, inventive and has a technical character.

The Art. 123(2) & (3) EPC headache – Why?

Although the patent laws of other countries contain similar patentability requirements, few patent offices are as strict in applying this as the EPO. According to the EPO, any amendments to the claims must be directly and unambiguously derivable from the application as originally filed.

Priority IP